What is Catalyst Pharmaceutical's SG&A?

Catalyst Pharmaceutical (CPRX) reported SG&A of $49.32M in Q1 2026.

How has Catalyst Pharmaceutical's SG&A changed year-over-year?

Catalyst Pharmaceutical's SG&A increased by 5.1% year-over-year, from $46.91M to $49.32M.

What is the long-term trend for Catalyst Pharmaceutical's SG&A?

Over 4 years (2021 to 2025), Catalyst Pharmaceutical's SG&A has grown at a 40.6% compound annual growth rate (CAGR), from $49.63M to $193.75M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Catalyst Pharmaceutical CPRX SG&A

SG&A at other companies

PTC TherapeuticsPTCT

$86.18M+6.5%

Acadia PharmaceuticalsACAD

$171.02M+35.3%

Amneal Pharmaceuticals, Inc.AMRX

$138.86M+17.4%

Rhythm Pharmaceuticals, Inc.RYTM

$63.59M+62.7%

Mirum Pharmaceuticals, Inc.MIRM

$96.33M+66.9%

LQD

Liquidia CorporationLQDA

$46.94M+56.1%

Other financials

Income statement

See full

Revenue$149.4M+5.6%

Gross profit$134.9M+9.2%

Operating income$73.2M+15.6%

Net income$63.7M+12.3%

EPS (diluted)$0.50+11.1%

Balance sheet

See full

Cash & equivalents$755.9M+30.2%

Total debt$2.7M-13.3%

Total equity$1.0B+27.5%

Total assets$1.1B+26.3%

Cash flow

See full

Operating cash flow$59.6M-0.8%

CapEx$27.0K—

Free cash flow$59.6M-0.8%

Valuation

See full

Market cap$3.84B+2.7%

Enterprise value$3.09B-4.1%

P/E17.4×-1.6×

P/S6.4×-0.6×

Profitability

See full

Gross margin86%-0.2pp

Operating margin44.8%+1.6pp

Net margin37.1%+0.2pp

FCF margin34.9%-15.2pp

Returns & leverage

See full

Return on equity24.5%-4.6pp

Debt / equity0×0.0×

Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Catalyst Pharmaceutical's SG&A?: Catalyst Pharmaceutical (CPRX) reported SG&A of $49.32M in Q1 2026.
How has Catalyst Pharmaceutical's SG&A changed year-over-year?: Catalyst Pharmaceutical's SG&A increased by 5.1% year-over-year, from $46.91M to $49.32M.
What is the long-term trend for Catalyst Pharmaceutical's SG&A?: Over 4 years (2021 to 2025), Catalyst Pharmaceutical's SG&A has grown at a 40.6% compound annual growth rate (CAGR), from $49.63M to $193.75M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.